{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibj7cz2npvcpiyd2g67m5oz3bftr7fpvav35ldfeul23uvllgbyia",
    "uri": "at://did:plc:ox2kiwcr2xmn32p25g472pp7/app.bsky.feed.post/3ml74h6cbdc22"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidwyxdz4sr7xaeumklcmpcwrwxzgvqei2b54z3xpovj2a45we3mem"
    },
    "mimeType": "image/webp",
    "size": 68402
  },
  "path": "/releases/2026/05/260505234618.htm",
  "publishedAt": "2026-05-06T02:20:17.000Z",
  "site": "https://www.sciencedaily.com",
  "textContent": "A short burst of immunotherapy before surgery is delivering surprisingly powerful results for a specific type of colorectal cancer. Patients in a UK-led trial who received just nine weeks of pembrolizumab prior to surgery have remained cancer-free nearly three years later—an outcome that challenges the standard approach of surgery followed by months of chemotherapy.",
  "title": "Colon cancer breakthrough keeps patients cancer-free for nearly 3 years"
}